UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL			
OMB Number	3235-02		

87 Estimated average burden 0.5 hours per response..

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(11iiit of Type	e Responses)														
1. Name and Address of Reporting Person * McGrath Lynne Fahey				2. Issuer Name and Ticker or Trading Symbol Alzamend Neuro, Inc. [ALZN]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner					
(Last) (First) (Middle) 3802 SPECTRUM BOULEVARD, SUITE 112C				3. Date of Earliest Transaction (Month/Day/Year) 10/15/2021						_	Officer (give	title below)	Other	(specify below	<i>i</i>)
(Street)			4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing/Check Applicable Line) X_Form filed by One Reporting Person Even filed by Mary then One Reporting Person					
TAMPA, FL 33612									Form filed by More than One Reporting Person						
(City)		(State)	(Zip)			Table I -	- Non-Der	ivative S	Securities	Acquire	d, Disposed	of, or Benef	icially Owner	i	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)			(Instr. 8		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		f (D) Ov	Amount of S wned Following ansaction(s)		d (Ownership Form:	Beneficial	
				(Month/D	Day/Yeai	Code	e V	Amount	(A) or (D)	(In	(I)		r Indirect	Ownership (Instr. 4)	
Common S	Stock		10/15/2021			M(1		47,222	· · ·		0,000		`)	
Reminder: Re	eport on a sep	parate line for each o	class of securities be	eneficially	owned d	irectly or	Persor in this	s who i	e not re	quired to	o respond เ		on containe form displa		474 (9-02)
Reminder: Ro	eport on a sep	parate line for each of	Table II -	Derivative	e Securi	ies Acqui	Persor in this a curre	s who iform arently val	e not re lid OMB or Benef	quired to control icially Ov	o respond u number.				474 (9-02)
Reminder: Ro	2. Conversion	3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivative (e.g., puts, 4. Transacti Code	5. Non of D Security Acquired or D	ries Acqui arrants, o umber erivative rities uired (A) isposed D) r. 3, 4,	Persor in this a curred, Dispoptions, co	osed of, convertible ercisable	e not re lid OMB or Benef le securit e and	quired to control icially Ow ties)	orespond unumber. vned and Amount clying s	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	7 10. Ownersh Form of Derivati Security Direct (I or Indirect)	11. Nature of Indire Benefic (Owners: (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	Derivative (e.g., puts, 4. Transacti Code (Instr. 8)	5. Non of D Security Acquired or D of (I	cies Acqui arrants, o umber erivative rrities aired (A) isposed D) r. 3, 4,	Persor in this a curred, Dispoptions, co	ns who is form are notify values of the control of	e not re lid OMB or Benef le securit e and	quired to control icially Ow ties) 7. Title a of Under Securities	orespond unumber. vned and Amount clying s	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	Ownersh Form of Derivating Security Direct (I or Indirection	ip of Indir Benefic Owners (Instr. 4

Reporting Owners

		Relationsl	nips	
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
McGrath Lynne Fahey 3802 SPECTRUM BOULEVARD, SUITE 112C TAMPA, FL 33612	X			

Signatures

/s/ Lynne F. McGrath	10/18/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the vesting of restricted stock.
- (2) Each restricted stock unit is the economic equivalent of one share of Common Stock, par value \$0.0001, of Alzamend Neuro, Inc.
- (3) The restricted stock grant was amended on October 13, 2021, such that 47,222 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock vested on October 15, 2021, and the remaining stock vested on October 15, 2021, and the remaining shall vest on March 15, 2022. 2,778 shares previously vested on September 13, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.